stepped out or regrouping, dude you literally do this as day...

stepped out or regrouping, dude you literally do this as day job, suddenly you stepped out, I have countered this many times to you and Mason, you are a master in repeating the same again and again, learn to read the website,

A trial that’s been shelved or terminated would typically be marked “Terminated,” “Withdrawn,” or “Suspended,” not “Active.”

Now you will say my beloved second screenshot gotcha its terminated if only if you knew what they mean

“Terminated” (NCT05311176)This means that specific gastric-cancer study was stopped early and will not enroll further patients. Reasons can include things like low enrollment, an interim data review, a strategic decision to move into a different indication, or safety signals.It does not necessarily imply that Imugene has abandoned HER-Vaxx altogether—only that this one protocol was halted.

“Completed” (NCT02795988)That second study ran its full course, enrolled patients, collected data, and reported results. A “Completed” status simply means they finished that trial as planned

Imugene is simply saying, “We now have both a CAR-T (Azer-Cel) and an onCARlytics vector. In the future, those two technologies can be combined (e.g. use onCARlytics to boost CD19 expression, then send in AZER-CEL to kill those CD19⁺ cells).”It does not imply anything about the fate of PD1-Vaxx (IMU-201).

IMU-201 (PD1-VAXX) in non–small cell lung cancer (NSCLC) is listed as “Active, not recruiting.” That means all patients have already been dosed and are now in follow-up for safety, immune responses, and any preliminary efficacy signals.

they will either secure a collaboration or material transfer agreement with a biotech developing a LAG-3 or TIGIT antibod or they will extend the design a small Phase I/II to test tri-therapy: PD1-VAXX + PD-1 mAb ( pembrolizumab) + LAG-3 inhibitor, focusing on “checkpoint relapse” cohorts (patients who failed prior PD-1), this is the natural progression...